GT
CRNX icon

Glenmede Trust’s Crinetics Pharmaceuticals CRNX Stock Holding History

Glenmede Trust’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.06M Buy
29,245
+12,301
+73% +$549K 0.01% 722
2025
Q4 		$789K Buy
+16,944
New +$754K ﹤0.01% 793
2025
Q1 		$582K Sell
17,352
-38
-0.2% -$1.42K ﹤0.01% 858
2024
Q4 		$889K Buy
17,390
+246
+1% +$13.8K ﹤0.01% 758
2024
Q3 		$876K Sell
17,144
-807
-4% -$41.6K ﹤0.01% 756
2024
Q2 		$804K Buy
17,951
+11,013
+159% +$509K ﹤0.01% 751
2024
Q1 		$325K Buy
+6,938
New +$271K ﹤0.01% 1035
2023
Q4 		– Sell
-7,518
Closed -$224K – 1305
2023
Q3 		$224K Buy
+7,518
New +$155K ﹤0.01% 1073

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return